Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May 26;16(6):11903-65.
doi: 10.3390/ijms160611903.

What's New in Traumatic Brain Injury: Update on Tracking, Monitoring and Treatment

Affiliations
Review

What's New in Traumatic Brain Injury: Update on Tracking, Monitoring and Treatment

Cesar Reis et al. Int J Mol Sci. .

Abstract

Traumatic brain injury (TBI), defined as an alteration in brain functions caused by an external force, is responsible for high morbidity and mortality around the world. It is important to identify and treat TBI victims as early as possible. Tracking and monitoring TBI with neuroimaging technologies, including functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI), positron emission tomography (PET), and high definition fiber tracking (HDFT) show increasing sensitivity and specificity. Classical electrophysiological monitoring, together with newly established brain-on-chip, cerebral microdialysis techniques, both benefit TBI. First generation molecular biomarkers, based on genomic and proteomic changes following TBI, have proven effective and economical. It is conceivable that TBI-specific biomarkers will be developed with the combination of systems biology and bioinformation strategies. Advances in treatment of TBI include stem cell-based and nanotechnology-based therapy, physical and pharmaceutical interventions and also new use in TBI for approved drugs which all present favorable promise in preventing and reversing TBI.

Keywords: biomarker; electrophysiology; genomic; hypothermia; microdialysis; nano particle; neuroimaging; proteomic; stem cell; traumatic brain injury.

PubMed Disclaimer

References

    1. Hayes R.L., Jenkins L.W., Lyeth B.G. Neurotransmitter-mediated mechanisms of traumatic brain injury: Acetylcholine and excitatory amino acids. J. Neurotrauma. 1992;9(Suppl. 1):S173–S187. - PubMed
    1. Faden A.I. Pharmacologic treatment of acute traumatic brain injury. JAMA. 1996;276:569–570. doi: 10.1001/jama.1996.03540070065034. - DOI - PubMed
    1. McIntosh T.K., Saatman K.E., Raghupathi R., Graham D.I., Smith D.H., Lee V.M., Trojanowski J.Q. The dorothy russell memorial lecture. The molecular and cellular sequelae of experimental traumatic brain injury: Pathogenetic mechanisms. Neuropathol. Appl. Neurobiol. 1998;24:251–267. doi: 10.1046/j.1365-2990.1998.00121.x. - DOI - PubMed
    1. McIntosh T.K., Juhler M., Wieloch T. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: 1998. J. Neurotrauma. 1998;15:731–769. doi: 10.1089/neu.1998.15.731. - DOI - PubMed
    1. Kermer P., Klöcker N., Bähr M. Neuronal death after brain injury. Models, mechanisms, and therapeutic strategies in vivo. Cell Tissue Res. 1999;298:383–395. doi: 10.1007/s004410050061. - DOI - PubMed

Substances